AbbVie’s Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on AbbVie (ABBV – Research Report). The associated price target remains the same with $250.00.

Terence Flynn has given his Buy rating due to a combination of factors that highlight AbbVie’s promising growth trajectory. The company has a strong pipeline, particularly in immunology with Skyrizi, which is well-positioned in both psoriasis and inflammatory bowel disease. Flynn anticipates continued market share growth for Skyrizi, driven by its favorable profile and data.
Additionally, AbbVie’s strategic investments in oncology, including antibody drug conjugates and next-generation CAR-T therapies, demonstrate its commitment to innovation and expansion. The company’s recent platform technology deals further provide growth optionality over the next eight years. Flynn also notes AbbVie’s interest in obesity treatments as a potential growth pillar, alongside its active business development efforts in China, which are outpacing some areas of US innovation.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABBV in relation to earlier this year.